Company intelligence / Profile preview

AptaBio Therapeutics Inc.

Yongin-si, Gyeonggi-do, South Koreamarketscreener.com ↗

Ownership: Private
Development stage: Phase 2

Overview

The company's lead candidate isuzinaxib (APX-115) has shown positive topline data in European Phase 2 clinical trials for diabetic nephropathy and is also being evaluated for contrast-induced acute kidney injury. The company has multiple candidates in clinical and preclinical stages.

Therapeutic areas: GastroenterologyOncologyNephrologyOphthalmologyHematologyInfectious Diseases
Modalities: Small molecule drugsAptamer drug conjugatesChemical drugs
Industry: Biotech

Drug pipeline

9 assets

isuzinaxib

8 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with universities, hospitals, contract research organizations and contract manufacturing organizations

Beyond the preview

Go deeper on AptaBio Therapeutics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AptaBio Therapeutics Inc..

Explore the full profile